1-Month Extension of Co-Development Contract with Vanda Pharma
Vanda exercised its extension option, extending the contract period by 1 month to May 31, 2026 (from April 30).
Maintains co-development contract signed in 2022 for 2 drugs (rare disease and immuno-oncology) based on OliPass PNA platform.
Upfront payment of USD 3,000,000 (~KRW 4.3 billion) already received.
All R&D costs borne by Vanda; option exercise amount undisclosed (confidential until May 31, 2026).
Positive signal of Vanda's continued commitment and progress in new drug development.
KOSDAQ Filing Information
Filing: [Correction of Description] Material Information for Investment Decision (Signing of Joint Research and Development Agreement with Vanda Pharmaceuticals for Development of Rare Disease Treatments and Immuno-Oncology Drugs Based on OliPass PNA Platform Technology)